Sep 20, 2017 by Brian Feroldi, Rich Duprey, and Demitri Kalogeropoulos3 Stocks That Are Absurdly Cheap Right NowLooking for value in today's pricy market? These three stocks fit the bill.
Sep 19, 2017 by Brian FeroldiHere's Why Nabriva Therapeutics PLC Is Soaring TodayAnalyst upgrades and news that the company's balance sheet is getting a makeover caused traders to cheer.
Sep 19, 2017 by Brian Feroldi, Rich Duprey, and Demitri Kalogeropoulos3 Stocks That Could Soar More Than PricelineHint: One of them has crushed Priceline's return over the past five years.
Sep 19, 2017 by Brian Feroldi, Sean Williams, and George Budwell, PhD3 High-Yield Pharmaceutical StocksOn the hunt for a fat dividend yield? These three big pharma stocks deliver.
Sep 18, 2017 by Brian FeroldiWhy Nabriva Therapeutics PLC Is SkyrocketingShares soar after the company reports upbeat data from a pivotal clinical trial.
Sep 18, 2017 by Brian Feroldi, Sean Williams, and George Budwell, PhD3 High-Yield Healthcare StocksGlaxoSmithKline, HCP, and Pfizer all offer their shareholders fat payouts. Here's why income investors can safely buy each of these stocks today.
Sep 17, 2017 by Brian Feroldi, Reuben Gregg Brewer, and Keith Noonan3 Heirloom Stocks to Hold ForeverLooking for a few companies that you can pass on to your kids one day? Our team of investors thinks these three businesses are about as good as it gets.
Sep 16, 2017 by Brian Feroldi, Reuben Gregg Brewer, and Keith Noonan3 Stocks You Can Safely Own Until 2030Looking for a few great companies to buy and hold for the ultralong term? These three stocks fit the bill.
Sep 15, 2017 by Brian FeroldiHere's What Caused Arrowhead Pharmaceuticals' Stock to Spike TodayThe announcement of a new RNAi drug-development platform has traders feeling a bit giddy about the clinical-stage biotech.
Sep 15, 2017 by Brian Feroldi, Sean Williams, and George Budwell, PhD3 Dividend Healthcare StocksLooking for income from the healthcare sector? Here's why you should check out Gilead Sciences, Allergan, and LeMaitre Vascular.
Sep 14, 2017 by Brian FeroldiHere's Why Halozyme Therapeutics, Inc. Is Soaring TodayShareholders can look at a trio of positive updates for today's big jump.
Sep 12, 2017 by Brian FeroldiHere's Why Intercept Pharmaceuticals Is Tumbling TodayNews that a warning letter related to the company's drug Ocaliva was recently sent out to the healthcare community causes traders to head for the exits.
Sep 11, 2017 by Brian FeroldiMasimo Corporation Fell 12.7% in August -- but Why? Strong quarterly results and bullish guidance weren't enough to please Wall Street.
Sep 11, 2017 by Brian FeroldiWhy Teva Pharmaceutical Industries Ltd. (ADR) Is SoaringShares jump after the company announces that it has finally filled a key executive position.
Sep 9, 2017 by Brian Feroldi, Rich Duprey, and Demitri Kalogeropoulos3 Value Stocks for Wise InvestorsLooking for a bargain in today's pricey market? Here's why you should consider e.l.f. Beauty, Best Buy, and Ulta Beauty.
Sep 9, 2017 by Brian Feroldi, Reuben Gregg Brewer, and Keith Noonan3 Stocks at 52-Week Highs Still Worth BuyingRio Tinto plc, Take-Two Interactive, and Mazor Robotics just reached 52-week highs. Here's why our team thinks that it's still a great time to buy.
Sep 7, 2017 by Brian FeroldiWhy Intra-Cellular Therapies Is Surging Today Shares jumped after the company announced some upbeat clinical news and received an analyst upgrade.
Sep 7, 2017 by Brian FeroldiWhy Clovis Oncology Fell 7.1% in AugustShares retreated after the company reported mixed quarterly results.
Sep 7, 2017 by Brian FeroldiWhy Illumina Rose 18.7% in AugustThe market cheered blowout quarterly results.
Sep 7, 2017 by Brian FeroldiHere's Why Cara Therapeutics Rose 9.6% in AugustTraders cheered better-than-expected quarterly results and some general company news.
